SEARCH

SEARCH BY CITATION

References

  • Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK et al. (2001). High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 47504755.
  • Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A et al. (2004). A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 64: 62006206.
  • Aires da Silva F, Santa-Marta M, Freitas-Vieira A, Mascarenhas P, Barahona I, Moniz-Pereira J et al. (2004). Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J Mol Biol 340: 525542.
  • Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R et al. (2006). Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Bioconjug Chem 17: 410418.
  • Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G et al. (2008). Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 68: 143151.
  • Armour KL, Van De Winkel JG, Williamson LM, Clark MR (2003). Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 40: 585593.
  • Baty D, Behar G, Chartier M, Pelegrin A, Teillaud JL, Teulon I (2006). Production of antibody formats and immunological applications of said formats. In WO/2006/064136.
  • Beckman RA, Weiner LM, Davis HM (2007). Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109: 170179.
  • Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C et al. (2008). Isolation and characterization of anti-Fc{gamma}RIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 21: 110.
  • Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM et al. (1988). Single-chain antigen-binding proteins [published erratum appears in Science 1989 Apr 28; 244 (4903): 409. Science 242: 423426.
  • Blick SK, Curran MP (2007). Certolizumab pegol: in Crohn's disease. BioDrugs 21: 195201. discussion 202–3.
  • Boldicke T (2007). Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med 11: 5470.
  • Borrebaeck CA, Carlsson R (2001). Human therapeutic antibodies. Curr Opin Pharmacol 1: 404408.
  • Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. (2002). Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754758.
  • Chames P, Baty D (2000). Antibody engineering and its applications in tumor targeting and intracellular immunization. FEMS Microbiol Lett 189: 18.
  • Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R (2006). FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 24: 28852890.
  • Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM et al. (2004). Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA 101: 1761617621.
  • Courtete J, Sibler AP, Zeder-Lutz G, Dalkara D, Oulad-Abdelghani M, Zuber G et al. (2007). Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA. Mol Cancer Ther 6: 17281735.
  • Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG et al. (2006). Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24: 15911597.
  • De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R et al. (2004). A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 64: 48704874.
  • Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007). Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 12: 898910.
  • Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002). Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195: 125133.
  • Dooley H, Flajnik MF, Porter AJ (2003). Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol Immunol 40: 2533.
  • Doorbar J, Griffin H (2007). Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin Biol Ther 7: 677689.
  • Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H et al. (2005). Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116: 304313.
  • Eshhar Z (2008). The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 329342.
  • Fischer N, Leger O (2007). Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74: 314.
  • Fujimori K, Covell DG, Fletcher JE, Weinstein JN (1990). A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31: 11911198.
  • Gillies SD, Lan Y, Williams S, Carr F, Forman S, Raubitschek A et al. (2005). An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105: 39723978.
  • Giritch A, Marillonnet S, Engler C, Van Eldik G, Botterman J, Klimyuk V et al. (2006). Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 103: 1470114706.
  • Graumann K, Premstaller A (2006). Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 1: 164186.
  • Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB et al. (1993). Naturally occurring antibodies devoid of light chains. Nature 363: 446448.
  • Holliger P, Hudson PJ (2005). Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 11261136.
  • Holliger P, Prospero T, Winter G (1993). ‘Diabodies’: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90: 64446448.
  • Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND et al. (2008). Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 21: 283288.
  • Hoogenboom HR, Chames P (2000). Natural and designer binding sites made by phage display technology. Immunol Today 21: 371378.
  • Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522525.
  • Kaspar M, Trachsel E, Neri D (2007). The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 67: 49404948.
  • Kohler G, Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495497.
  • Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L et al. (2006). Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103: 40054010.
  • Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N et al. (2006). Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24: 210215.
  • Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995). Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155: 219225.
  • Lo AS, Zhu Q, Marasco WA (2008). Intracellular antibodies (intrabodies) and their therapeutic potential. In: Y.Chernajovsky, A.Nissim (Eds) Therapeutic Antibodies. Handbook of Experimental Pharmacology, Volume 181, pp. 343373. Springer-Verlag: Berlin Heidelberg.
  • Lonberg N (2008). Human monoclonal antibodies from transgenic mice. In: Y.Chernajovsky, A.Nissim (Eds) Therapeutic Antibodies. Handbook of Experimental Pharmacology, Volume 181, pp. 6997. Springer-Verlag: Berlin Heidelberg.
  • Luginbuhl B, Kanyo Z, Jones RM, Fletterick RJ, Prusiner SB, Cohen FE et al. (2006). Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol 363: 7597.
  • Lynch SM, Zhou C, Messer A (2008). An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 377: 136147.
  • McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552554.
  • Manikandan J, Pushparaj PN, Melendez AJ (2007). Protein i: interference at protein level by intrabodies. Front Biosci 12: 13441352.
  • Matsushita M, Matsui H (2005). Protein transduction technology. J Mol Med 83: 324328.
  • Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S (2008). Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 36: 9971003.
  • Muller D, Kontermann RE (2007). Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 9: 319326.
  • Muller D, Karle A, Meissburger B, Hofig I, Stork R, Kontermann RE (2007). Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 282: 1265012660.
  • Nechansky A, Schuster M, Jost W, Siegl P, Wiederkum S, Gorr G et al. (2007). Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol Immunol 44: 18151817.
  • Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH (1985). A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314: 268270.
  • Nguyen A, Reyes AE 2nd, Zhang M, McDonald P, Wong WL, Damico LA et al. (2006). The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 19: 291297.
  • Nimmerjahn F, Ravetch JV (2007). Antibodies, Fc receptors and cancer. Curr Opin Immunol 19: 239245.
  • Paganetti P, Calanca V, Galli C, Stefani M, Molinari M (2005). beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol 168: 863868.
  • Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007). Immunotoxin treatment of cancer. Annu Rev Med 58: 221237.
  • Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z (2005). Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther 4: 18011809.
  • Preithner S, Elm S, Lippold S, Locher M, Wolf A, Da Silva AJ et al. (2006). High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 43: 11831193.
  • Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005). Monoclonal antibody successes in the clinic. Nat Biotechnol 23: 10731078.
  • Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA et al. (2008). Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res 14: 875882.
  • Roopenian DC, Akilesh S (2007). FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715725.
  • Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A et al. (2006). Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods 3: 887889.
  • Ruf P, Lindhofer H (2001). Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 25262534.
  • Shen J, Zhu Z (2008). Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther 10: 273284.
  • Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J et al. (2001). High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276: 65916604.
  • Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M et al. (2003). The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278: 34663473.
  • Siberil S, Dutertre CA, Boix C, Bonnin E, Menez R, Stura E et al. (2006). Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett 106: 111118.
  • Smith GP (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228: 13151317.
  • Stocks M (2006). Intracellular antibodies: a revolution waiting to happen? Curr Opin Mol Ther 8: 1723.
  • Stork R, Muller D, Kontermann RE (2007). A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 20: 569576.
  • Stork R, Zettlitz KA, Muller D, Rether M, Hanisch FG, Kontermann RE (2008). N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 283: 78047812.
  • Tanaka T, Lobato MN, Rabbitts TH (2003). Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. J Mol Biol 331: 11091120.
  • Tanaka T, Williams RL, Rabbitts TH (2007). Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. Embo J 26: 32503259.
  • Vaccaro C, Zhou J, Ober RJ, Ward ES (2005). Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23: 12831288.
  • Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A (2002). The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol 317: 7383.
  • Visintin M, Quondam M, Cattaneo A (2004). The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation. Methods 34: 200214.
  • Visintin M, Melchionna T, Cannistraci I, Cattaneo A (2008). In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an ‘undruggable’ class of disease targets. J Biotechnol 135: 115.
  • Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G (1989). Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli [see comments. Nature 341: 544546.
  • Weng WK, Levy R (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 39403947.
  • Willemsen RA, Debets R, Chames P, Bolhuis RL (2003). Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 64: 5668.
  • Williams BR, Zhu Z (2006). Intrabody-based approaches to cancer therapy: status and prospects. Curr Med Chem 13: 14731480.
  • Winter G, Milstein C (1991). Man-made antibodies. Nature 349: 293299.
  • Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA (2005). BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 10: 12371244.
  • Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R et al. (2004). Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87: 614622.
  • Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B et al. (1999). Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163: 12461252.